- Registration Date 2017-02-15
- Hit 14163
Company Information |
|
1. Name |
ANTEROGEN |
2. Website Address |
http://www.anterogen.com |
3. Location |
(Namsung Plaza, Gasan-dong) 405, 130 Digital-ro, Geumcheon-gu, Seoul (08589), South Korea |
4. Contacts |
+82 2 2104 0391 |
Pharmaceutical Product Information |
|
1. Brand Name |
Cupistem® |
2. Active Ingredient |
Autologous adipose tissue-derived mesenchymal stem cell |
3. Indication |
Crohn’s Fistula |
4. Information |
Cupistem® was approved as adipose tissue-derived mesenchymal stem cell (ASC) product first time in the world by Korean Ministry of Food and Drug Safety (MFDS) as of Jan 2012 and its medical insurance price was granted as of Jan 2014 by Health Insurance Review & Assessment Service (HIRA). The most remarkable feature of this product comes from its sustainability of therapeutic efficacy. Cupistem® showed that 82% of patients with complex Crohn’s fistula achieved complete healing at week 8 after treatment, 81% out of them sustained response at week 96. Anterogen explained this astonishing sustainability of product efficacy from immune modulation effect by ASC manufactured by Anterogen. |
5. Images |
|
Pharmaceutical Product Information |
|
1. Brand Name |
Queencell® |
2. Active Ingredient |
Autologous adipose tissue-derived adipose cell by minimal manipulation |
3. Indication |
Subcutaneous tissue defect |
4. Information |
Queencell® was approved as “autologous adipose tissue-derived adipose cell produced by minimal manipulation” by Korean Ministry of Food and Drug Safety (MFDS) as of Mar 2010. Queencell® is comprised of stromal vascular fraction (SVF) that is a heterogeneous mixture of mesenchymal stem cells and other cell types such as preadipocytes, endothelial progenitor cells, pericytes, mast cells, and fibroblast. Queencell® is effective in treating subcutaneous tissue defect. |
5. Images |
|
Division
Written by 한지혜